Dogwood Therapeutics, Inc. Announces Low Dose Imc-2 Treatment Reduces Long-Covid Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study
Dogwood Therapeutics公司宣佈,在一項由研究員發起的研究中,低劑量Imc-2治療減少了與長期新冠相關的疲勞和睡眠障礙
Dogwood Therapeutics, Inc. Announces Low Dose Imc-2 Treatment Reduces Long-Covid Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study
Dogwood Therapeutics公司宣佈,在一項由研究員發起的研究中,低劑量Imc-2治療減少了與長期新冠相關的疲勞和睡眠障礙
譯文內容由第三人軟體翻譯。